Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
A83-01 (HB3218)
Description:Selective TGF-βRI (ALK5), ALK4 and ALK7 inhibitor. Maintains human hiPSC self renewal, 3D growth matrix component and promotes long-term organoid growth. Aids fibroblast to NSC/cardiomyocyte reprogramming.
Purity:>98%
AM 404 (HB1174)
Description:Selective, competitive carrier-mediated anandamide transport inhibitor
Purity:>98%
Amitriptyline hydrochloride (HB1794)
Description:Serotonin/norepinephrine reuptake inhibitor (SNRI)
Purity:>98%